OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-59.52M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -49.01% |
| Return on Assets (Trailing 12 Months) | -45.77% |
| Current Ratio (Most Recent Fiscal Quarter) | 26.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 26.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 40.40M |
| Free Float | 39.52M |
| Market Capitalization | $143.81M |
| Average Volume (Last 20 Days) | 0.16M |
| Beta (Past 60 Months) | 0.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.17% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |